Michael J Ramirez MD
Instructor, Medical Oncology, Jefferson Medical College-Thos Jefferson Univ
Join to View Full Profile
925 Chestnut StSte 320APhiladelphia, PA 19107
Phone+1 215-955-8874
Fax+1 215-955-2340
Dr. Ramirez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1995 - 1998
Temple University HospitalResidency, Internal Medicine, 1991 - 1994
Lewis Katz School of Medicine at Temple UniversityClass of 1991
Certifications & Licensure
PA State Medical License 1993 - 2026
DE State Medical License 2018 - 2025
NJ State Medical License 2018 - 2025
NC State Medical License 1995 - 1998
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013
Clinical Trials
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Jul 28
- Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma Start of enrollment: 2009 Feb 05
- A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer Start of enrollment: 2011 May 25
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsPhase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.Jonathan Pan, Sushil Ghimire, S. Onder Alpdogan, Andrew E. Chapman, Matthew Carabasi
Leukemia & Lymphoma. 2021-02-23 - 72 citationsPhase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.Gregory J. Kubicek, Maria Werner-Wasik, Mitchell Machtay, Gayle Mallon, Thomas J. Myers
International Journal of Radiation Oncology, Biology, Physics. 2009-06-01 - 78 citationsComparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapyLyndsay Harris, Vlayka Liotcheva, Gloria Broadwater, Michael J. Ramirez, Peter Maimonis
Journal of Clinical Oncology. 2001-03-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
